Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Video of Dr. Lilge's recent webinar - 119 mins.

<< Previous

Bullboard Posts

Next >>

Comment by socksnblonds642on Aug 25, 2021 12:48pm

204 Views

Post# 33761441

RE:RE:Video of Dr. Lilge's recent webinar - 119 mins.

Definitely look fwd to Ego and CS input on the tech side. My takeaway is that Dr Lilge and team are devising a metric to compare PDT's and that he will be releasing a paper comparing them. He said his focus has been mainly on Ruthinium based PD's lately...look fwd to seeing that

The metric may be the number of photon's absorbed per cubic cm to achieve cell death. The point is to establish a benchmark so that the PDT's can be compared. A pretty important step. Risk vs reward I guess. How much is absorbed by the target cell what risks there are for the adjacent healthy cells

<< Previous

Bullboard Posts

Next >>

Soma Gold poised to extend profitable track record